DCTH vs INVA: fair value comparison
Delcath Systems, Inc. and Innoviva, Inc. · Updated 2026-10-19
DCTH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DCTH currently ranks higher by quality score.
| DCTH | INVA | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $14.08 | $20.78 |
| 12-month range | $8.19–$17.36 | $17.57–$24.24 |
| Rank by discount to fair value | — | #43 of 108 Healthcare |
| Rank by quality score | #2 of 301 Healthcare | #4 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | — | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | — | Undervalued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: DCTH fair value analysis · INVA fair value analysis